FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

[1]  M. Taniwaki,et al.  Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. , 2012, Current cancer drug targets.

[2]  M. Taniwaki,et al.  RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma , 2012, Molecular Cancer Therapeutics.

[3]  B. Turk,et al.  Lysosomal pathways to cell death and their therapeutic applications. , 2012, Experimental cell research.

[4]  L. Kappos,et al.  Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study , 2012, The Lancet Neurology.

[5]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[6]  B. Balint,et al.  Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy. , 2012, Vojnosanitetski pregled.

[7]  T. Taki,et al.  Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia , 2011, Proceedings of the National Academy of Sciences.

[8]  M. Copland,et al.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. , 2011, Blood.

[9]  S. Rafii,et al.  Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. , 2011, Cancer cell.

[10]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[11]  S. McKenna,et al.  Autophagy induction by Bcr‐Abl‐expressing cells facilitates their recovery from a targeted or nontargeted treatment , 2011, American journal of hematology.

[12]  J. Liao,et al.  Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. , 2010, Blood.

[13]  M. Deininger,et al.  Faculty of 1000 evaluation for Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010 .

[14]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[15]  J. Melo,et al.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR , 2010, Leukemia.

[16]  T. Tsuruo,et al.  Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment , 2010, Cell Death and Differentiation.

[17]  L. Ashman,et al.  Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. , 2010, Cancer research.

[18]  M. Taniwaki,et al.  Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia , 2010, Molecular Cancer Research.

[19]  Manuel Ayala,et al.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.

[20]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[21]  J. Byrd,et al.  FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma , 2010, Clinical Cancer Research.

[22]  M. Carroll,et al.  BCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia , 2010, Leukemia.

[23]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[24]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[25]  M. Taniwaki,et al.  Involvement of BH3-only proteins in hematologic malignancies. , 2009, Critical reviews in oncology/hematology.

[26]  J. Martinez-Climent,et al.  Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. , 2009, European journal of cancer.

[27]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[28]  R. Zini,et al.  Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. , 2008, Blood.

[29]  S. Toyokuni,et al.  The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias , 2008, Cell Death and Differentiation.

[30]  M. Konopleva,et al.  CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells , 2008, Molecular Cancer Therapeutics.

[31]  A. Strasser,et al.  ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms , 2007, British journal of haematology.

[32]  J. Byrd,et al.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. , 2008, Blood.

[33]  T. Holyoake,et al.  Characterization of cancer stem cells in chronic myeloid leukaemia. , 2007, Biochemical Society transactions.

[34]  M. Caligiuri,et al.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. , 2007, The Journal of clinical investigation.

[35]  A. Strasser,et al.  Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia , 2007, Cell Death and Differentiation.

[36]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[37]  Christine Barett,et al.  Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. , 2006, Blood.

[38]  T. Graeber,et al.  Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants , 2006, Proceedings of the National Academy of Sciences.

[39]  A. Strasser,et al.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic , 2006, Proceedings of the National Academy of Sciences.

[40]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[41]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[42]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[43]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[44]  C. van Hoof,et al.  PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.

[45]  E. Suzuki,et al.  Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[47]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[48]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[49]  Katsuo Suzuki,et al.  Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. , 2003, International journal of oncology.

[50]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[51]  H. Kantarjian,et al.  Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. , 2002, Cancer research.

[52]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[53]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[54]  N. Nonomura,et al.  Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling, FAK, cell‐cycle entry and apoptosis , 2002, International journal of cancer.

[55]  N. Ichimaru,et al.  Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. , 2002, Cancer research.

[56]  V. Brinkmann,et al.  FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. , 2001, Transplantation proceedings.

[57]  JS Damiano,et al.  Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation , 2001, Leukemia.

[58]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[59]  V. Janssens,et al.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.

[60]  Y. Takagi,et al.  Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers , 2000, Gut.

[61]  G. Russo,et al.  Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms , 2000, Oncogene.

[62]  G. Russo,et al.  Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. , 2000, Oncogene.

[63]  H. Amemiya,et al.  An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL‐60 , 1997, Immunology.